adMare
News
June 07 2022
adMare Porfolio Company Find Therapeutics Signs Licensing agreement to Develop a Promising New Therapy for Multiple Sclerosis and Other Demyelinating Diseases
Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.
June 07 2022
adMare Portfolio Company FORUS Therapeutics Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada
FORUS Therapeutics Inc ("FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
June 01 2022
Anie Perrault joins adMare as Vice President, Public Affairs and Communications
adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications.
May 18 2022
adMare Appoints Dr. Christine Allen as Vice-President, Ecosystem Development
Toronto May 18, 2022 – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong…
May 10 2022
adMare BioInnovations joins a $42m Series A financing in Domain Therapeutics
Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in…
May 02 2022
adMare Portfolio Company, Zucara Therapeutics Secures Additional Funding for the Development of ZT-01
Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…
April 22 2022
Join Us on May 30th, for the Official Opening of adMare’s Montreal Innovation Centre Expansion & BIOQuébec’s 2022 AGA
adMare BioInnovations and BIOQuébec cordially invite you to join your fellow Quebec life sciences leaders for a very special evening to celebrate the official opening of adMare’s new facility. Special guests will…
April 12 2022
Read the newest issue of the adMare Quarterly newsletter – April 12, 2022
adMare Quarterly It has been a busy few months at adMare! From a transformative investment of $92M recently announced by the Minister of Innovation, Science and Industry at our Innovation…
April 08 2022
Building Canada’s Life Sciences Industry on a Strong Foundation of Canadian Talent
Labour shortages are hitting virtually every Canadian sector, from coffee shops to car manufacturing – and life sciences is no exception. But what is exceptional about our industry is its…
April 05 2022
adMare BioInnovations Collaborates with Accelerator Company, Molecular Forecaster Inc. on Computational Approaches to Drug Discovery
MONTREAL, QUEBEC, April 5, 2022 – Molecular Forecaster Inc. (MFI) is excited to announce a partnership with adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D…
March 30 2022
Government of Canada Invests $92 million in adMare to help translate health research into innovative new therapies in Canada
GOVERNMENT OF CANADA RELEASE Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development March 30, 2022 – Vancouver, British Columbia –…
March 16 2022
Listen to adMare’s President & CEO, Gordon C. McCauley on CGEn’s New Podcast, Synapsis
adMare’s President & CEO, Gordon C. McCauley speaks with Dr. Naveed Aziz on the first episode of CGEn’s new podcast, Synapsis, about the health sciences sector and what can be…
March 11 2022
adMare supports Ukraine; Responds to Ministers Champagne and Duclos
Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health issued a statement on additional measures in response to Vladimir Putin’s…
March 08 2022
Join Us For adMare’s Lunch & Learn: Building Talent with Amplitude Ventures March 17, 2022
The Amplitude Fellowship – Training the next generation of life science entrepreneurs Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor? Do you want to…
March 08 2022
Join Us For adMare’s Global Leaders Webinar Featuring Dr. Robert Langer April 19, 2022
adMare Global Leaders Webinar From Lab bench to clinic: How to solve global health challenges by developing new therapies through innovation and founding new companies Featuring Dr. Robert Langer adMare’s…
February 14 2022
adMare Portfolio Company, Find Therapeutics, Appoints Dr. Philippe Douville as Chief Executive Officer
MONTREAL, Feb. 14, 2022 – Find Therapeutics Inc. (‘Find’) is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer. Dr. Douville brings to Find 25…
February 08 2022
adMare Portfolio Company, Zucara Therapeutics Announces Publication of Preclinical Study
Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…
January 17 2022
Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses…
January 13 2022
adMare Portfolio Company NIMIUM Therapeutics’ Research Breakthrough Shows Promise To Maintain Good Health As We Age
MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate…
January 12 2022
adMare Portfolio Company Neurasic Therapeutics Receives New Grant to Advance Non-Opioid Pain Treatment
Montréal – Québec – January 12th, 2022 –CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative…
December 21 2021
adMare Quarterly
In this issue of adMare Quarterly, we are pleased to share our latest news on building companies, building ecosystems, and building talent to build the Canadian life sciences industry from sea to sea – along with Season’s Greetings and a look back on some 2021 highlights from adMare.
December 16 2021
Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations
Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December…
December 15 2021
Join Us for adMare’s Industry Builder Webinar Featuring Dr. Michel Bouvier – Jan. 17, 2022
Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs? Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier…
November 18 2021
adMare BioInnovations Announces Successful Applicants to 2021-2022 Executive Institute
Vancouver, BC and Montreal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of…
November 15 2021
adMare BioInnovations and uOttawa Work Together to Translate University Research into Strong New Canadian Life Science Companies
Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the…
November 09 2021
adMare BioInnovations and CASTL Partner to Build Canada’s Biomanufacturing Talent
Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership…
November 02 2021
adMare BioInnovations and District 3 Innovation partner to provide science-based Canadian startups more cohesive support to grow into industry leaders
MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry…
October 21 2021
adMare’s President & CEO Gordon C. McCauley is Appointed to BIOVECTRA Board of Directors
Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex…
September 28 2021
adMare’s Accelerate Quebec Company, Molecular Forecaster, Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships
The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…
September 17 2021
adMare Portfolio Company, Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL)…
September 13 2021
adMare Portfolio Company BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related…
July 06 2021
New life sciences company takes aim at obesity, toxic effects of overnutrition — NIMIUM Therapeutics launches in Montreal
A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases. The company’s foundational technology is based on the cutting-edge research…
June 03 2021
CPDC/adMare Radiopharmaceutical Initiative (CARI): New blog post – Q&A session with our experts
Over the past few months, adMare BioInnovations and the Centre for Probe Development and Commercialization (CPDC) have shared with you information about the role and the potential of radiopharmaceuticals in…
May 17 2021
adMare and AazeinTx Inc Sign Global Exclusive Agreement
adMare BioInnovations (“adMare”) and AazeinTx Inc. (“AazeinTx”) have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860,…
April 12 2021
adMare BioInnovations launches Canada’s first & only digital life sciences community
In our COVID world, we all need to get creative in building new ways to safely and effectively come together. The pandemic is showing us that Canada needs strong life sciences…
February 10 2021
Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada
Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people…
February 10 2021
Soundbite Medical Solutions Announces Health Canada Approval for SoundBite® Crossing System ‐ Peripheral (14P)
Soundbite announces Health Canada Approval for SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SCS-P (14P) is intended for the treatment of patients suffering from peripheral…
January 27 2021
New Canadian Pharmaceutical Company Brings Novel Cancer Therapies To Market
FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment…
January 14 2021
adMare Launches Abdera with AbCellera as a Founding Partner
adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company…
December 11 2020
Join us in the 50 – 30 Challenge
adMare is proud to be an early adopter of the Government’s 50 – 30 Challenge to accelerate diversity and inclusion in our workforce at the senior leadership level. To build…
December 10 2020
adMare BioInnovations Welcomes the First Quebec Start-Ups in its Accelerate Program
adMare today unveiled the six companies selected under its new acceleration program supported by the Quebec Government and the City of Montreal. Montréal, QC – December 10, 2020 – adMare BioInnovations,…
December 02 2020
Event: Announcement of the Companies Selected Under adMare Accelerate Program
adMare BioInnovations, Canada’s global life sciences venture, invites you to join us on Thursday, December 10 at 11:00 am (EST), for the unveiling of the six exciting start-ups selected for our new…
November 26 2020
adMare’s cross-Canada virtual roadtrip – British Columbia Stop
COVID-19 may be keeping us from getting on planes and meeting in person, but it’s not stopping us from continuing to build Canada’s life sciences industry from sea to sea,…
November 26 2020
Radiopharmaceuticals: a new class of drugs for cancer patients, and a new road for Canada to lead global life sciences
The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada…
November 16 2020
Developing Canada’s Next Generation of Commercial Life Scientists
adMare Academy Responds to Pandemic with New Pan-Canadian BioInnovation Scientist Program November 16, 2020: adMare BioInnovations, Canada’s global life sciences venture, is proud to announce the launch of its new…
November 02 2020
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
October 15 2020
Didier Leconte Elected Chair of adMare Board
Vancouver and Montréal, Canada – October 15, 2020: adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the election of Mr. Didier Leconte, Vice President, Investments – Life Sciences…
September 30 2020
Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative
If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020. What is CARI?…
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall, 4th Floor
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
